ANI Pharmaceuticals, Inc. (ANIP) — Analysis Summary
ANI Pharmaceuticals, Inc. (ANIP) has a market cap of $1.84B with year-over-year revenue growth of +43.8%. Net margin stands at 8.9%. The stock trades at a P/E ratio of 20.0.
Key Takeaways
- Revenue changed +43.8% year-over-year
- Net margin of 8.9%
- P/E ratio of 20.0
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ANIP posted revenue growth of +43.8% and trades at a P/E of 20.0.
ANI Pharmaceuticals, Inc. (ANIP)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
970
Headquarters
PRINCETON, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.